APP
CRSP icon

Alpha Paradigm Partners’s CRISPR Therapeutics CRSP Stock Holding History

Alpha Paradigm Partners’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-6,628
Closed -$403K – 493
2022
Q2 		$403K Sell
6,628
-13,700
-67% -$805K 0.17% 219
2022
Q1 		$1.28M Buy
+20,328
New +$1.28M 0.5% 38

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Alpha Paradigm Partners's CRSP Position: Q3 2022 in Review

Alpha Paradigm Partners sold out of CRISPR Therapeutics (CRSP) in Q3 2022, closing a stake of 6,628 shares — an estimated $403K sold.

Alpha Paradigm Partners first reported a position in CRSP in Q1 2022 and held it in 2 quarters. The position peaked at $1.28M in Q1 2022. 436 funds tracked by Wall St. Rank hold CRSP as of Q3 2022.

  • Alpha Paradigm Partners reported no remaining CRISPR Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Alpha Paradigm Partners sold 6,628 CRISPR Therapeutics shares in Q3 2022, an estimated $403K.
  • Alpha Paradigm Partners first reported a position in CRISPR Therapeutics in Q1 2022 and held it in 2 quarters.
  • Alpha Paradigm Partners's CRISPR Therapeutics position peaked at $1.28M in Q1 2022.
  • 436 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2022.

Based on Alpha Paradigm Partners's 13F filing for Q3 2022, filed 15 Nov 2022.